FCER2 and carcinoma: In FDC-S diagnosis, FDCSP and SRGN showed both a good sensitivity, higher than CD23 and Claudin 4, and an extremely good specificity, evaluated on 214 controls including carcinomas, soft tissue tumors, melanomas, thymomas and interdigitating dendritic cell sarcomas.